Czech National Bank Purchases 20,087 Shares of Merck & Co., Inc. $MRK

Czech National Bank grew its position in Merck & Co., Inc. (NYSE:MRK) by 3.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 654,472 shares of the company’s stock after acquiring an additional 20,087 shares during the quarter. Czech National Bank’s holdings in Merck & Co., Inc. were worth $68,890,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Brighton Jones LLC raised its position in Merck & Co., Inc. by 29.5% in the 4th quarter. Brighton Jones LLC now owns 38,278 shares of the company’s stock worth $3,808,000 after purchasing an additional 8,710 shares during the period. Sivia Capital Partners LLC boosted its position in shares of Merck & Co., Inc. by 52.2% during the second quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company’s stock valued at $910,000 after buying an additional 3,941 shares during the period. Laurel Wealth Advisors LLC grew its stake in shares of Merck & Co., Inc. by 7,567.9% during the second quarter. Laurel Wealth Advisors LLC now owns 489,209 shares of the company’s stock valued at $38,726,000 after buying an additional 482,829 shares during the last quarter. FourThought Financial Partners LLC grew its stake in shares of Merck & Co., Inc. by 8.3% during the second quarter. FourThought Financial Partners LLC now owns 6,599 shares of the company’s stock valued at $522,000 after buying an additional 507 shares during the last quarter. Finally, North Star Asset Management Inc. raised its holdings in shares of Merck & Co., Inc. by 1.6% in the second quarter. North Star Asset Management Inc. now owns 11,996 shares of the company’s stock worth $950,000 after buying an additional 192 shares during the period. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Stock Up 2.5%

Shares of NYSE MRK opened at $119.33 on Thursday. Merck & Co., Inc. has a 52-week low of $73.31 and a 52-week high of $125.14. The firm has a market capitalization of $295.04 billion, a price-to-earnings ratio of 16.39, a PEG ratio of 2.25 and a beta of 0.27. The stock has a 50 day moving average price of $116.27 and a 200 day moving average price of $101.44. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.30 and a current ratio of 1.54.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Tuesday, February 3rd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $2.01 by $0.03. The company had revenue of $16.40 billion for the quarter, compared to the consensus estimate of $16.19 billion. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.Merck & Co., Inc.’s quarterly revenue was up 5.0% on a year-over-year basis. During the same period last year, the business posted $1.72 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Sell-side analysts expect that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 16th will be given a dividend of $0.85 per share. The ex-dividend date of this dividend is Monday, March 16th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.8%. Merck & Co., Inc.’s dividend payout ratio is presently 46.70%.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck agreed to acquire Terns Pharmaceuticals for $53.00 per share (~$6.7B) to add TERN-701, an allosteric BCR::ABL1 candidate for chronic myeloid leukemia — seen as a strategic, near-term pipeline boost ahead of Keytruda patent risk. Merck to Acquire Terns Pharmaceuticals press release
• Positive Sentiment: Analysts highlight TERN-701’s disruptive potential in CML; some firms say the deal strengthens Merck’s long-term oncology franchise and could be accretive if the asset delivers. Health Care Roundup: Market Talk
• Positive Sentiment: Broker action: Citi recently raised its price target on MRK to $125 (from $120), signaling continued analyst support amid the M&A and pipeline moves. Citi Raises its Price Target on Merck
• Positive Sentiment: Market backdrop helped equities broadly: risk-on sentiment (hopes for a ceasefire in the Middle East) and lower oil prices supported healthcare stocks, including MRK. Equities Rise, Oil Dips as Traders Weigh Prospects of Iran War Ceasefire
• Neutral Sentiment: Merck announced a multi‑year collaboration with Quotient Therapeutics on IBD target discovery (potential upside, but long‑term and milestone‑driven). Quotient Therapeutics Announces Collaboration with Merck
• Neutral Sentiment: Merck hosted/announced investor and M&A calls to discuss the transaction and strategy — useful for details but not an immediate catalyst beyond confirmation of deal terms. Merck & Co., Inc. (MRK) M&A Call Transcript
• Negative Sentiment: Deal risks: reporting notes potential for a bidding contest or activist interest — that could raise acquisition cost or create execution risk; investors may watch for how Merck finances / integrates the asset. Why Merck Might Have A Fight On Its Hands With Its $6.7 Billion Takeover Of Terns

Insider Activity

In related news, CMO Chirfi Guindo sold 20,000 shares of Merck & Co., Inc. stock in a transaction dated Thursday, February 5th. The stock was sold at an average price of $121.88, for a total value of $2,437,600.00. Following the completion of the sale, the chief marketing officer directly owned 80,615 shares in the company, valued at $9,825,356.20. The trade was a 19.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Robert M. Davis sold 47,434 shares of the company’s stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $118.04, for a total transaction of $5,599,109.36. Following the completion of the sale, the chief executive officer directly owned 443,602 shares of the company’s stock, valued at approximately $52,362,780.08. This trade represents a 9.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 320,176 shares of company stock valued at $38,281,735. Company insiders own 0.13% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Deutsche Bank Aktiengesellschaft raised Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $150.00 price target for the company in a research note on Friday, February 13th. Citigroup increased their target price on Merck & Co., Inc. from $120.00 to $125.00 and gave the stock a “neutral” rating in a research note on Friday, March 20th. Wells Fargo & Company lifted their target price on Merck & Co., Inc. from $135.00 to $150.00 and gave the stock an “overweight” rating in a research report on Thursday, March 12th. Morgan Stanley boosted their target price on shares of Merck & Co., Inc. from $100.00 to $102.00 and gave the company an “equal weight” rating in a research note on Friday, December 12th. Finally, Royal Bank Of Canada began coverage on shares of Merck & Co., Inc. in a report on Wednesday, February 25th. They issued an “outperform” rating and a $142.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $127.13.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.